FrancophonIA/ELRC3.0 huggingface dataset:
English: At steady-state, the dosenormalized plasma levels of the parent compound, quetiapine, in children and adolescents (10-17 years of age) were in general similar to adults, though Cmax in children was at the higher end of the range observed in adults.
Maltese: Fi stat fiss, il-livelli fil-plażma tas-sustanza oriġinali, quetiapine, normalizzati mad-doża, fi tfal u adolexxenti (10-17-il sena) kienu b'mod ġenerali simili għal dawk fl-adulti, għalkemm is-Cmax fi tfal kien fil-parti għolja tal-medda li dehret fl-adulti.
English: Seroquel Prolong 50 mg prolonged-release tablets
Maltese: Seroquel Prolong 50 mg prolongedrelease tablets
English: Patients treated with any antipsychotic agent including quetiapine, should be observed for signs and symptoms of hyperglycaemia, (such as polydipsia, polyuria, polyphagia and weakness) and patients with diabetes mellitus or with risk factors for diabetes mellitus should be monitored regularly for worsening of glucose control.
Maltese: Pazjenti li jkunu qed jiġu ikkurati bu kwalunkwe mediċina antipsikotika inkluż quetiapine, għandhom jiġu osservati għal sinjali u sintomi ta' ipergliċemija, (bħal polidipjsa, polijurja, polifaġja u dgħjufija) u pazjenti b'dijabete mellitus jew b'fatturi ta' riskju għal dijabete mellitus għandhom jiġu monitorati b'mod regolari, għal meta jiħżien il-kontroll taz-zokkor.
English: The CHMP concluded that there is potential benefit in the use of quetiapine as an add-on treatment of major depressive episodes in patients with MDD who have sub-optimal response to antidepressant monotherapy.
Maltese: Is-CHMP ikkonkluda li hemm benefiċċju potenzjali fl-użu ta' quetiapine bħala trattament addizzjonali ta' episodji depressivi maġġuri f'pazjenti b'MDD li ma jkollhomx rispons tajjeb biżżejjed għallmonoterapija bl-antidepressanti.
English: Based on these in vitro results, it is unlikely that coadministration of quetiapine with other drugs will result in clinically significant drug inhibition of cytochrome P450 mediated metabolism of the other drug.
Maltese: Minn dawn ir-riżultati in vitro, mhux probabbli li l-għotja ta' quetiapine ma' mediċini oħra twassal għal inibizzjoni tal-mediċina klinikament sinifikanti talmetaboliżmu tal-mediċina l-oħra medjat permezz ta' cytochrome P450.
English: Quetiapine should be used with caution in patients at risk for aspiration pneumonia.
Maltese: Quetiapine għandu jintuża b'kawtela f'pazjenti li jkollhom riskju ta pnewmonja b'aspirazzjoni.
English: - The Committee considered the referral made under article 6(13) Commission Regulation (EC) No 1084/2003, for Seroquel XR and associated names initiated by the MAH (see annex I).
Maltese: - Il-Kumitat ikkunsidra r-referenza li saret skont l-Artikolu 6(13) tar-Regolament talKummissjoni (KE) Nru 1084/2003, għal Seroquel XR u l-ismijiet assoċjati mibdija mill-MAH (ara anness I).
English: Seroquel Prolong 300 mg prolonged-release tablets
Maltese: Seroquel Prolong 300 mg prolongedrelease tablets
English: Core
Maltese: Billi
English: Clinical trials with Seroquel have shown that in addition to the known safety profile identified in adults (see section 4.8), certain adverse events occurred at a higher frequency in children and adolescents compared to adults (increased appetite, elevations in serum prolactin and extrapyramidal symptoms) and one was identified that has not been previously seen in adult studies (increases in blood pressure).
Maltese: Provi kliniċi b'Seroquel urew li minbarra l-profil ta' sigurtà identifikat fl-adulti (ara sezzjoni 4.8), ċerti każijiet avversi seħħew b'frekwenza ogħla fi tfal u adolexxenti meta mqabbla ma' l-adulti (żieda fl-aptit, żiediet tal-prolactin fis-serum u sintomi ekstrapiramidali) u wieħed kien identifikat li ma deherx fl-adulti (żiediet fil-pressjoni tad-demm).
English: Seroquel XR dose can be adjusted depending on clinical response and tolerability of the individual patient within the dose range of 300 mg to 800 mg/day.
Maltese: Id-doża ta' Seroquel XR tista' tiġi aġġustata skond ir-rispons kliniku u t-tollerabilità tal-pazjent individwali fil-medda tad-doża ta' 300 mg għal 800 mg/jum.
English: The CHMP concluded that the safety profile for add-on treatment in short-term studies was similar to the safety demonstrated for mono-therapy.
Maltese: Is-CHMP ikkonkluda li l-profil ta' sigurtà għat-trattament addizzjonali fl-istudji fuq żmien qasir kien simili għas-sigurtà li ntweriet għall-monoterapija.
English: The proportion of randomized patients over 75 years of age was 19%.
Maltese: Il-proporzjon ta' pazjenti randomised fuq il-75 sena kienet 19%.
English: Lot
Maltese: FOLJA
English: In a long-term open label study with Seroquel of schizophrenia and bipolar mania, the aggregated incidence of treatment-emergent EPS was 10%.
Maltese: Fi studju fuq żmien twil b'Seroquel ta' skizofrenija u manija bipolari, il-frekwenza kollettiva tal-kura ta' EPS li ħarġu kienet 10%.
English: Thioridazine (another anti-psychotic medicine).
Maltese: jew xi antibijotiċi (mediċini li jfejqu l-infezzjonijiet)
English: Since patients treated with antipsychotics often present with acquired risk factors for VTE, all possible risk factors for VTE should be identified before and during treatment with SEROQUEL XR and preventive measures undertaken.
Maltese: Minħabba li pazjenti li jiġu ikkurati b'antipsikotiċi ħafna drabi jiġu b'fatturi ta' riskju għal VTE li jkunu meħuda, ir-riskju kollha ta' VTE li jista' jkun hemm għandhom jiġu identifikati qabel u waqt il-kura b'SEROQUEL XR u jittieħdu miżuri ta' prevenzjoni.
English: • Fits or seizures
Maltese: • Aċċessjonijiet
English: On 22 May 2009, the MAH triggered a referral under Article 6(13) of Commission Regulation (EC) No 1084/2003, requesting the CHMP to consider whether it is appropriate to introduce Seroquel XR, at 50 - 300 mg/day dosage to a population of patients with major depressive disorders, excluding the use as initial treatment and used when patients cannot be appropriately managed on alternative antidepressant treatment.
Maltese: Fit-22 ta' Mejju 2009, il-MAH ta bidu għal referenza skont l-Artikolu 6(13) tar-Regolament talKummissjoni (KE) Nru 1084/2003, li fiha talab lis-CHMP jikkunsidra jekk huwiex xieraq li Seroquel XR jiġi introdott f'dożi ta' 50 - 300 mg/jum lil popolazzjoni ta' pazjenti b'disturbi depressivi maġġuri, minbarra l-użu bħala trattament inizjali u jintuża meta l-pazjenti ma jistgħux jiġu kkontrollati kif xieraq permezz ta' trattament b'antidepressanti alternattivi.
English: Seroquel Depot United Kingdom Seroquel XL
Maltese: KIF GĦANDEK TUŻA SEROQUEL XR
English: HOW TO STORE SEROQUEL XR
Maltese: QABEL MA TUŻA SEROQUEL XR
English: Efficacy and safety has not been evaluated in patients over 65 years with depressive episodes in the framework of bipolar disorder.
Maltese: L-effikaċja u s-sigurtà ma ġewx stabbiliti f'pazjenti ‘l-fuq minn 65 sena b'episodji depressivi flambitu ta' disturb bipolari.
English: • Discontinuation symptoms (symptoms which occur when you stop taking Seroquel XR) include not being able to sleep (insomnia), feeling sick (nausea), headache, diarrhoea, being sick
Maltese: • Sintomi ta' twaqqif (sintomi li jseħħu meta tieqaf tieħu Seroquel XR) jinkludu li ma tkunx tista torqod (insomnja), dardir, uġigħ ta' ras, dijarea, rimettar, sturdut jew tkun irritat.
English: In placebo-controlled trials with quetiapine the mean change and the incidence of patients who have a shift to a clinically significant level is similar between quetiapine and placebo.
Maltese: Fi provi kliniċi ikkontrollati, ma kienx hemm differenza fil-frekwenza ta' l-aċċessjonijiet f'pazjenti b'quetiapine jew plaċebo.
English: The effect size of the 600 mg and 800 mg doses was greater than that of the 400 mg dose.
Maltese: Id-daqs ta' l-effett tad-dożi ta' 600 mg u 800 mg kien akbar minn dak tad-doża ta' l-400 mg.
English: As quetiapine is extensively metabolised by the liver, elevated plasma levels are expected in the population with hepatic impairment.
Maltese: Minħabba li quetiapine jiġi metabolizzat b'mod estensiv mill-fwied, livelli għoljin fil-plażma huma mistennija fil-popolazzjoni b'indeboliment epatiku.
English: Endocrine disorders
Maltese: Disturbi gastro-intestinali
English: Cardiac disorders Common:
Maltese: Reazzjoni anafilattika Disturbi fis-sistema endokrinarja Komuni:
English: In placebo-controlled monotherapy trials in patients with a baseline neutrophil count ≥ 1.5 X 109/L, the incidence of at least one occurrence of neutrophil count <1.5 X 109/L, was 1.72% in patients treated with quetiapine compared to 0.73% in placebo-treated patients.
Maltese: 109/L, kien 1.72% f'pazjenti ikkurati b'quetiapine meta mqabbel ma' 0.73% fil-pazjenti ikkurati bilplaċebo.
English: Read the package leaflet before use.
Maltese: Mhux iddaqsijiet kollha tal-pakkett huma għal skopijiet kummerċjali.
English: Elevations in blood creatine phosphokinase15
Maltese: ANNESS II KONKLUŻJONIJIET XJENTIFIĊI
English: For add-on treatment of major depressive episodes in MDD:
Maltese: Pazjenti anzjani bi psikożi relatata mad-demenzja:
English: Quetiapine treatment was associated with small dose-related decreases in thyroid hormone levels, particularly total T4 and free T4.
Maltese: Il-kura b'quetiapine kienet assoċjata ma' tnaqqis żgħir fil-livelli tat-tajrojd relatati mad-doża, l-aktar itT4 totali u T4 ħieles.
English: Based on shifts above clinically significant thresholds (adapted from the National Institutes of Health criteria) or increases >20mmHg for systolic or >10 mmHg for diastolic blood pressure at any time in two acute (3-6 weeks) placebo-controlled trials in children and adolescents.
Maltese: Ibbażat fuq bidliet il-fuq minn limiti klinikament sinifikanti (adottati minn kriterji ta' Istituti Nazzjonali tas-Saħħa) jew żiediet ta' >20 mmHg għal dik sistolika jew ta' >10 mmHg għal pressjoni dijastolika tad-demm fi kwalunkwe ħin f'żewġ provi ikkontrolati bil-plaċebo akuti (3-6 ġimgħat) fi tfal u adolexxenti.
English: • Unpleasant sensations in the legs (also called restless legs syndrome).
Maltese: • Sensazzjonijiet mhux pjaċevoli fis-saqajn (tissejjaħ ukoll sindrome tas-saqajn irrikwieti)
English: • Do not use Seroquel XR after the expiry date which is stated on the container after EXP.
Maltese: • Tużax Seroquel XR wara d-data ta' skadenza li tidher fuq il-pakkett wara EXP.
English: 100 prolonged-release tablets
Maltese: 400 mg Prolonged-release tablet
English: In rats, pigment deposition in the thyroid gland has been observed; in cynomolgus monkeys thyroid follicular cell hypertrophy, a lowering in plasma T3 levels, decreased haemoglobin concentration and a decrease of red and white blood cell count have been observed; and in dogs lens opacity and cataracts.
Maltese: Fil-firien, dehret depożizzjoni tal-pigment fil-glandola tat-tajrojd, f'xadini ċinomolgus ipertrofija taċċelluli follikulari tat-tajrojd, tnaqqis fil-livelli ta' T3 fil-plażma, deher tnaqqis tal-konċentrazzjoni ta' lemoglobina u tnaqqis fl-għadd taċ-ċelluli ħomor u bojod tad-demm; u fi klieb opaċità tal-lenti u katarretti.
English: Hypromellose
Maltese: FARMAĊEWTIKU
English: Important information about some of the ingredients of Seroquel XR Seroquel XR contains lactose which is a type of sugar.
Maltese: Fiż-żewġ studji, pazjenti li kienu magħrufa li Serqouel ma jaħdimx fuqhom kienu esklużi.
English: In five placebo controlled monotherapy studies (including a study in elderly subjects) the effects of quetiapine in an unrestricted MDD population were shown.
Maltese: F'ħames studji ta' monoterapija kkontrollati bi plaċebo (inkluż studju f'suġġetti anzjani) intwerew leffetti ta' quetiapine f'popolazzjoni b'MDD mhux ristretta.
English: Pregnancy and breast-feeding
Maltese: Disturbi fil-metaboliżmu u n-nutrizzjoni
English: For patients who were randomized to quetiapine, the mean weight gain during the open label period was 2.56 kg, and by week 48 of the randomized period, the mean weight gain was 3.22 kg, compared to open label baseline.
Maltese: Kg, u mat-48 ġimgħa talperjodu randomised, il-medja ta' żieda fil-piż kien ta' 3.22 Kg, mqabbel mal-linja bażi open-label.
English: During post-marketing experience, resolution of leucopenia and/or neutropenia has followed cessation of therapy with quetiapine.
Maltese: Esperjenza ta' wara ttqegħid fis-suq , lewkopenija u/jew newtropenija fiequ wara li twaqqfet it-terapija b'quetiapine.
English: As Seroquel XR is indicated for the treatment of schizophrenia, bipolar disorder and add-on treatment of major depressive episodes in patients with MDD, the safety profile should be considered with respect to the individual patient's diagnosis and the dose being administered.
Maltese: Minħabba li Seroquel XR huwa indikat għall-kura ta' skizofrenija, disturb bipolari u kura miżjuda ghal-epsiodji ta' depressjoni kbira f'pazjenti b'MDD, il-profil ta' sigurtà għandu jitqies fid-dawl taddijanjosi individwali tal-pazjent u d-doża li tkun qed tingħata.
English: An approximately 3-fold increased risk of cerebrovascular adverse events has been seen in randomised placebo controlled trials in the dementia population with some atypical antipsychotics.
Maltese: Madwar żieda ta' 3-darbiet tar-riskju ta' każijiet ċerebrovaskulari dehret fi provi kontrollati bi plaċebo fil-popolazzjoni b'demenzja b'xi antipsikotiċi mhux tipiċi.
English: This belongs to a group of medicines called antipsychotics.
Maltese: Dan jippartjeni lil grupp ta' mediċini li jissejħu antipsikotiċi.
English: As a consequence of this interaction, lower plasma concentrations can occur, which could affect the efficacy of Seroquel XR therapy.
Maltese: Hemm riskju akbar ta' effetti avversi b'dożi ogħla.
English: Children and Adolescents:
Maltese: Tfal u adolexxenti:
English: The most commonly reported Adverse Drug Reactions (ADRs) with quetiapine are somnolence, dizziness, dry mouth, mild asthenia, constipation, tachycardia, orthostatic hypotension and dyspepsia.
Maltese: L-aktar Reazzjonijiet Avversi tal-Mediċina (ADRs) irrappurtati b'mod komuni b'quetiapine huma ngħas, sturdament, ħalq xott, astenija ħafifa, stitikezza, takikardija, pressjoni li titbaxxa mal-pożizzjoni u dispepsja.
English: In short term, fixed dose (50mg/d to 800 mg/d), placebo-controlled studies (ranging from 3 to 8 weeks), the mean weight gain for quetiapine-treated patients ranged from 0.8 kg for the 50 mg daily dose to 1.4 kg for the 600 mg daily dose (with lower gain for the 800 mg daily dose), compared to 0.2 kg for the placebo treated patients.
Maltese: Fi provi kliniċi fuq żmien qasir, b' doża fissa (50 mg/d sa 800 mg/d) ikkontrollati bi plaċebo (bejn 3 sa 8 ġimgħat), il-medja ta' żieda fil-piż għall-pazjenti kkurati b' quetiapine varja minn 0.8
English: The absolute bioavailability is 88%.
Maltese: Il-bijodisponibilità assoluta hija ta' 88%.
English: ATC vet code: QP54AB51.
Maltese: QP54AB51.
English: The absolute bioavailability is 81% and 65% for the A3 and A4 forms, respectively.
Maltese: Il-bijodisponibilità assoluta huwa ta' 81% u ta' 65% għall-forom A3 u A4, rispettivament.
English: Date of first authorisation: 15/01/2015 Date of last renewal:
Maltese: Data tal-ewwel awtorizzazzjoni: 15/01/2015
English: Prevention of Angiostrongylosis:
Maltese: Prevenzjoni ta' angiostrongylosis:
English: It is a fermentation product of Streptomyces milbemycinicus.
Maltese: Huwa prodott ta' fermentazzjoni tal-Streptomyces milbemycinicus.
English: Pharmacotherapeutic group: antiparasitic products, endectocides, milbemycin combinations.
Maltese: Grupp farmakoterapewtiku: prodotti antiparassitiċi, endektoċidi, taħlitiet ta' milbemycin.
English: Treatment of demodicosis (caused by Demodex canis).
Maltese: Kura ta' demodikosi (ikkawżata minn Demodex canis)
English: Manufacturer responsible for batch release: MERIAL,
Maltese: Manifattur responsabbli għall-ħrug tal-lott: MERIAL,
English: Milbemycin oxime distributes into tissues with a volume of distribution of 2.7 ± 0.4 l/kg and 2.6 ± 0.6 l/kg for the A3 and A4 forms, respectively.
Maltese: Milbemycin oxime jiġi distribwit fit-tessuti b'volum ta' distribuzzjoni ta' 2.7 ± 0.4 l/kg u 2.6 ± 0.6 l/kg għall-forom A3 u A4 rispettivament.
English: NEXGARD SPECTRA is not indicated for microfilariae clearance.
Maltese: NEXGARD SPECTRA mhux indikat għat-tneħħija tal-mikrofilarji.
English: Method of administration:
Maltese: Mod t'amministrazzjoni:
English: Milbemycin oxime is an antiparasitic endectocide belonging to the group of macrocyclic lactones.
Maltese: Milbemycin oxime huwa endektoċida antiparassita li jappartjeni għall-grupp ta' lactones makroċikliċi.
English: The terminal half-lives and maximum concentrations (Cmax) following oral administration are 1.6 ± 0.4 days and 42 ± 11 ng/ml for the A3 form, 3.3 ± 1.4 days and 246 ±71 ng/ml for the A4 form.
Maltese: Il-half-lives tal-plasma terminali u l-konċentrazzjonijiet massimi (Cmax) wara amministrazzjoni orali huma 1.6 ± 0.4 ġranet u 42 ± 11 ng/ml għall-forma A3, 3.3 ± 1.4 ġranet u 246 ± 71 ng/ml għall-forma A4.
English: Afoxolaner acts as an antagonist at ligand-gated chloride channels, in particular those gated by the neurotransmitter gamma-aminobutyric acid (GABA).
Maltese: Afoxolaner jaġixxi bħala antagonist fil-kanali ta' ligand-gated chloride, b'mod partikulari dawk gated minnewrotrasmettitur gamma-aminobutyric acid (GABA).
English: Afoxolaner distributes into tissues with a volume of distribution of 2.6 ± 0.6 l/kg and a systemic clearance value of 5.0 ± 1.2 ml/h/kg.
Maltese: Afoxolaner jiġi distribwit fit-tessuti b'volum ta' distribuzzjoni ta' 2.6 ± 0.6 l/kg u valur ta' tneħħija sistemika ta' 5.0 ± 1.2 ml/siegħa/kg.
English: Both forms have low systemic clearance (75 ± 22 ml/h/kg for the A3 form and 41 ± 12 ml/h/kg for the A4 form).
Maltese: Iż-żewġ forom għandhom valur ta' tneħħija sistemika baxx (75 ± 22 ml/h/kg għall-forma A3 u 41 ± 12 ml/h/kg għall-forma A4).
English: Dogs 2-3.5 kg Dogs >3.5-7.5 kg Dogs >7.5-15 kg Dogs >15-30 kg Dogs >30-60 kg
Maltese: Klieb 2-3.5 mg Klieb > 3.5−7.5 kg Klieb > 7.5−15 kg Klieb > 15−30 kg Klieb > 30−60 kg
English: The mean maximum concentration (Cmax) is 1822 ± 165 ng/ml in plasma found 2-4 hours (Tmax) after a 2.5 mg/kg afoxolaner dose.
Maltese: Il-konċentrazzjoni massima medja (Cmax) kienet 1,822 ± 165 ng/ml fi plasma 2 4 sigħat (Tmax) wara doża ta' afoxolaner ta' 2.5 mg/kg.
English: Milbemycin oxime contains two major components, A3 and A4 (ratio of 20:80 for A3:A4).
Maltese: Milbemycin oxime għandu żewġ komponenti prinċipali , A3 u A4 (ratio ta' 20:
English: The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reaction(s) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
Maltese: Il-frekwenza ta' effetti mhux mixtieqa hija definita skont din il-konvenzjoni: - komuni ħafna (aktar minn wieħed f'10 annimali kkurati li juru effett mhux mixtieq (effetti mhux mixtieqa) - komuni (aktar minn wieħed iżda inqas minn 10 annimali f'100 annimal ikkurat) - mhux komuni (aktar minn wieħed iżda inqas minn10 annimali f'1,000 annimal ikkurat) - rari (aktar minn wieħed iżda inqas minn10 annimali f'10,000 annimal ikkurat) - rari ħafna (inqas minn annimal wieħed f'10,000 annimal ikkurat, inklużi rapporti iżolati).
English: Prevention of heartworm disease (Dirofilaria immitis larvae) with monthly administration.
Maltese: Prevenzjoni ta' heartworm disease (Dirofilaria immitis larvae) b'amministrazzjoni kull xahar.
English: Use only according to the benefit-risk assessment by the responsible veterinarian.
Maltese: riskju mill-veterinarju responsabbli.
English: The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reaction(s)) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
Maltese: - mhux komuni (aktar minn wieħed iżda inqas minn10 annimali f'1,000 annimal ikkurat) - rari (aktar minn wieħed iżda inqas minn10 annimali f'10,000 annimal ikkurat) - rari ħafna (inqas minn annimal wieħed f'10,000 annimal ikkurat, inklużi rapporti iżolati).
English: Each chewable tablet contains 9.375 mg afoxolaner and 1.875 mg milbemycin oxime Each chewable tablet contains 18.75 mg afoxolaner and 3.75 mg milbemycin oxime Each chewable tablet contains 37.5 mg afoxolaner and 7.5 mg milbemycin oxime Each chewable tablet contains 75 mg afoxolaner and 15 mg milbemycin oxime Each chewable tablet contains 150 mg afoxolaner and 30 mg milbemycin oxime
Maltese: Kull pillola li tintmagħad fiha 18.75 mg/ afoxolaner u 3.75 mg milbemycin oxime Kull pillola li tintmagħad fiha 37.5mg/ afoxolaner u 7.5 mg milbemycin oxime Kull pillola li tintmagħad fiha 75 mg/ afoxolaner u 15 mg milbemycin oxime Kull pillola li tintmagħad fiha 150 mg/ afoxolaner u 30 mg milbemycin oxime
English: Milbemycin oxime is active against several gastrointestinal worms (Toxocara canis, Toxascaris leonina, Ancylostoma caninum, Ancylostoma braziliense, Ancylostoma ceylanicum, Trichuris vulpis), the adults and immature adults (L5) of lungworm Angiostrongylus vasorum and heartworm (Dirofilaria immitis larvae).
Maltese: Milbemycin oxime huwa attiv kontra diversi dud gastrointestinali (Toxocara canis, Toxascaris leonina, Ancylostoma caninum, Ancylostoma braziliense, Ancylostoma ceylanicum, Trichuris vulpis), l-adulti u adulti immaturi (L5) ta' lungworm Angiostrongylus vasorum u heartworm (larvae tadDirofilaria immitis).
English: Treatment of flea infestations (Ctenocephalides felis and C. canis) in dogs.
Maltese: Kura ta' infestazzjonijiet bi briegħed (Ctenocephalides felis u C. canis) fil-klieb
English: 1 chewable tablet 3 chewable tablets 6 chewable tablets 15 chewable tablets
Maltese: 3 pilloli li jintmagħdu 6 pilloli li jintmagħdu 15-il pillola li jintmagħdu
English: It is active against adult fleas as well as against several tick species such as Rhipicephalus sanguineus, Dermacentor reticulatus and D. variabilis, Ixodes ricinus and I. scapularis, Amblyomma americanum, and Haemaphysalis longicornis.
Maltese: Huwa attiv kontra l-briegħed adulti kif ukoll speċi differenti ta' qurdien bħal Rhipicephalus sanguineus, Dermacentor reticulatus, D. variabilis, Ixodes ricinus,u I. Scapularis, Amblyomma americanum, u Haemaphysalis longicornis.
English: It is active against adult fleas as well as against several tick species such as Rhipicephalus sanguineus, Dermacentor reticulatus and D. variabilis, Ixodes ricinus, Ixodes hexagonus and I. scapularis, Amblyomma americanum and Haemaphysalis longicornis.
Maltese: Huwa attiv kontra l-briegħed adulti kif ukoll speċi differenti ta' qurdien bħal Rhipicephalus sanguineus, Dermacentor reticulatus, D. variabilis, Ixodes ricinus, Ixodes hexagonus u I. Scapularis, Amblyomma americanum, u Haemaphysalis longicornis.
English: Treatment of tick infestations (Dermacentor reticulatus, Ixodes ricinus, Ixodes hexagonus, Rhipicephalus sanguineus) in dogs.
Maltese: Kura ta' infestazzjonijiet bil-qurdien (Dermacentor reticulatus, Ixodes ricinus, Ixodes hexagonus, Rhipicephalus sanguineus) fil-klieb.
English: Erythema and neurological signs (convulsions, ataxia and muscle tremors) have been reported very rarely.
Maltese: Eritema u sinjali newroloġiċi (konvulżjonijiet, ataxia u rogħda fil-muskoli) ġew irrappurtati rari ħafna.
English: Prevention of heartworm disease:
Maltese: Prevenzjoni tal-Marda tal-Heartworm:
English: Milbemycin oxime is a substrate for P-glycoprotein (P-gp) and therefore could interact with other P-gp substrates (for example, digoxin, doxorubicin) or other macrocyclic lactones.
Maltese: Milbemycin oxime huwa sottostrat għal P-glycoprotein (P-gp) u għaldaqstant jista' jinteraġixxi ma' sottostrati oħra P-gp (per eżempju, digoxin, doxorubicin) jew lactones makroċikliċi oħra.
English: Afoxolaner: Afoxolaner is an insecticide and acaricide of the isoxazoline family.
Maltese: Afoxolaner huwa insettiċida u akariċida li jappartjeni għall-familja ta' isoxazoline.